Oral Mucositis

8
Pipeline Programs
9
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
5
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Design Therapeutics
1 program
1
Low intensity laser for oral mucositisPhase 41 trial
Active Trials
NCT01876407UnknownEst. Jul 2016
EpicentRx
EpicentRxCA - La Jolla
2 programs
2
RRx-001Phase 21 trial
RRx-001Phase 21 trial
Active Trials
NCT05966194RecruitingEst. Oct 2025
NCT03515538CompletedEst. Oct 2020
CSL Behring
CSL BehringIL - Bradley
1 program
1
ALD518Phase 21 trial
Active Trials
NCT01403064Terminated76Est. Mar 2014
Soligenix
SoligenixPRINCETON, NJ
1 program
1
SGX942Phase 21 trial
Active Trials
NCT02013050Completed111Est. Sep 2016
Celldex Therapeutics
1 program
1
velaferminPhase 21 trial
Active Trials
NCT00323518Completed390Est. Aug 2008
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
CaphosolPhase 1/21 trial
Active Trials
NCT00901732Unknown100Est. Nov 2010
Swedish Orphan Biovitrum
1 program
1
PaliferminPhase 11 trial
Active Trials
NCT01163097CompletedEst. Jan 2011
Stuart Therapeutics
1 program
OM Pain AppN/A1 trial
Active Trials
NCT02727062TerminatedEst. Aug 2019
Camurus
CamurusSweden - Lund
1 program
episilN/A1 trial
Active Trials
NCT01684566CompletedEst. Sep 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Design TherapeuticsLow intensity laser for oral mucositis
EpicentRxRRx-001
EpicentRxRRx-001
SoligenixSGX942
CSL BehringALD518
Celldex Therapeuticsvelafermin
Jazz PharmaceuticalsCaphosol
Swedish Orphan BiovitrumPalifermin
Stuart TherapeuticsOM Pain App
Camurusepisil

Clinical Trials (10)

Total enrollment: 677 patients across 10 trials

NCT01876407Design TherapeuticsLow intensity laser for oral mucositis

Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer

Start: Jan 2013Est. completion: Jul 2016
Phase 4Unknown

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Start: Apr 2024Est. completion: Oct 2025
Phase 2Recruiting

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

Start: Jul 2018Est. completion: Oct 2020
Phase 2Completed

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

Start: Dec 2013Est. completion: Sep 2016111 patients
Phase 2Completed

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Start: Jul 2011Est. completion: Mar 201476 patients
Phase 2Terminated

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Start: May 2006Est. completion: Aug 2008390 patients
Phase 2Completed

Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

Start: May 2009Est. completion: Nov 2010100 patients
Phase 1/2Unknown

Study to Characterize the Effect of Heparin on Palifermin Activity

Start: Jul 2010Est. completion: Jan 2011
Phase 1Completed

Smartphone Pain App for Assessing Oral Mucositis Pain in Patients

Start: Feb 2018Est. completion: Aug 2019
N/ATerminated

A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis

Start: Feb 2013Est. completion: Sep 2013
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 677 patients
9 companies competing in this space